G&E HERBAL BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.1 TWD | -1.34% |
|
+0.34% | -4.37% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,973 | 2,004 | 1,940 | 1,558 | 2,972 | 3,440 |
| Enterprise Value (EV) 1 | 1,821 | 1,878 | 1,820 | 1,450 | 2,766 | 3,129 |
| P/E ratio | -87.2 x | -85.8 x | -136 x | -78.4 x | 403 x | 47.5 x |
| Yield | - | - | - | - | - | 0.92% |
| Capitalization / Revenue | 897 x | 114 x | 68.7 x | 63.4 x | 46 x | 19 x |
| EV / Revenue | 828 x | 107 x | 64.5 x | 59 x | 42.8 x | 17.2 x |
| EV / EBITDA | -58.3 x | -96.5 x | -291 x | -142 x | 186 x | 34.8 x |
| EV / FCF | -84.6 x | -85.6 x | -254 x | -263 x | 29.7 x | 46.1 x |
| FCF Yield | -1.18% | -1.17% | -0.39% | -0.38% | 3.37% | 2.17% |
| Price to Book | 2.66 x | 2.79 x | 2.76 x | 2.28 x | 4.3 x | 4.51 x |
| Nbr of stocks (in thousands) | 55,660 | 55,660 | 55,660 | 55,660 | 55,660 | 55,660 |
| Reference price 2 | 35.45 | 36.00 | 34.85 | 28.00 | 53.40 | 61.80 |
| Announcement Date | 3/29/19 | 5/21/20 | 3/31/21 | 3/28/22 | 3/29/23 | 3/20/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 2.2 | 17.55 | 28.23 | 24.57 | 64.61 | 181.4 |
| EBITDA 1 | -31.22 | -19.46 | -6.263 | -10.23 | 14.88 | 90.02 |
| EBIT 1 | -40.25 | -28.68 | -15.47 | -19.56 | 5.486 | 80.68 |
| Operating Margin | -1,829.73% | -163.36% | -54.81% | -79.61% | 8.49% | 44.47% |
| Earnings before Tax (EBT) 1 | -30.67 | -27.52 | -13.06 | -18.22 | 7.227 | 90.5 |
| Net income 1 | -22.62 | -23.36 | -14.3 | -19.88 | 7.381 | 72.4 |
| Net margin | -1,028.32% | -133.1% | -50.66% | -80.92% | 11.42% | 39.9% |
| EPS 2 | -0.4064 | -0.4198 | -0.2570 | -0.3572 | 0.1326 | 1.300 |
| Free Cash Flow 1 | -21.53 | -21.93 | -7.171 | -5.52 | 93.19 | 67.88 |
| FCF margin | -978.53% | -124.92% | -25.4% | -22.47% | 144.25% | 37.41% |
| FCF Conversion (EBITDA) | - | - | - | - | 626.1% | 75.4% |
| FCF Conversion (Net income) | - | - | - | - | 1,262.63% | 93.75% |
| Dividend per Share | - | - | - | - | - | 0.5700 |
| Announcement Date | 3/29/19 | 5/21/20 | 3/31/21 | 3/28/22 | 3/29/23 | 3/20/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 153 | 126 | 120 | 109 | 206 | 311 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -21.5 | -21.9 | -7.17 | -5.52 | 93.2 | 67.9 |
| ROE (net income / shareholders' equity) | -3.01% | -3.2% | -2.01% | -2.87% | 1.07% | 9.96% |
| ROA (Net income/ Total Assets) | -3.25% | -2.41% | -1.34% | -1.74% | 0.46% | 6.05% |
| Assets 1 | 696.4 | 971.2 | 1,066 | 1,142 | 1,588 | 1,196 |
| Book Value Per Share 2 | 13.30 | 12.90 | 12.60 | 12.30 | 12.40 | 13.70 |
| Cash Flow per Share 2 | 0.2300 | 0.0800 | 0.2600 | 0.2200 | 2.060 | 2.510 |
| Capex 1 | 9.72 | 6.41 | 5 | 1.77 | 2.95 | 5.52 |
| Capex / Sales | 441.73% | 36.5% | 17.71% | 7.21% | 4.57% | 3.04% |
| Announcement Date | 3/29/19 | 5/21/20 | 3/31/21 | 3/28/22 | 3/29/23 | 3/20/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -4.37% | 102M | |
| +39.33% | 6.11B | |
| -18.38% | 4.35B | |
| -9.17% | 3.19B | |
| +3.98% | 3.15B | |
| -3.41% | 2.51B | |
| +48.74% | 1.98B | |
| -4.82% | 1.74B | |
| -1.24% | 1.63B | |
| -8.96% | 1.6B |
- Stock Market
- Equities
- 4911 Stock
- Financials G&E Herbal Biotechnology Co., Ltd.
